We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    mvt-601-049
Previous Study | Return to List | Next Study

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04666129
Recruitment Status : Recruiting
First Posted : December 14, 2020
Last Update Posted : September 6, 2022
Sponsor:
Information provided by (Responsible Party):
Myovant Sciences GmbH

Brief Summary:
This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).

Condition or disease Intervention/treatment Phase
Metastatic Castration-Resistant Prostate Cancer Metastatic Castration-Sensitive Prostate Cancer Non-Metastatic Castration-Resistant Prostate Cancer Drug: Relugolix Drug: Abiraterone Drug: Prednisone Drug: Methylprednisolone Drug: Apalutamide Drug: Docetaxel Phase 1

Detailed Description:

This is a three-part, open-label, parallel-cohort study to assess the safety and tolerability of relugolix as the ADT component in combination treatment with abiraterone acetate plus a corticosteroid in patients with mCSPC or mCRPC (Part 1), apalutamide in patients with mCSPC or nmCRPC (Part 2), or docetaxel with or without prednisone in patients with mCSPC or mCRPC (Part 3).

The study will consist of a 45-day screening period followed by a 12-week treatment period with one of the three combination treatments (Parts 1, 2, or 3). All participants are required to have been treated with standard-of-care leuprolide acetate or a GnRH receptor antagonist (such as degarelix) in combination with either abiraterone plus prednisone. Participants will be transitioned from standard-of-care leuprolide acetate or the GnRH receptor antagonist to relugolix; with relugolix treatment initiated the day the next dose of leuprolide acetate or the GnRH antagonist is scheduled for administration with the prior dosing regimen of abiraterone acetate plus a corticosteroid, apalutamide, or docetaxel with or without prednisone being continued.

In addition to evaluating the safety and tolerability of relugolix, the study will also provide safety data as participants transition from injectable leuprolide acetate or degarelix to treatment with relugolix as the androgen-deprivation component of the treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Actual Study Start Date : February 18, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : November 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part 1: Relugolix plus Abiraterone plus a Corticosteroid
Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.
Drug: Relugolix

(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.

(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.

Other Names:
  • MVT-601
  • TAK-385
  • T-1331285
  • RVT-601
  • Orgovyx

Drug: Abiraterone
Abiraterone acetate (1000 mg [2 x 500-mg tablets]) or fine-particle abiraterone acetate (500 mg [4 x 125-mg tablets]) will be administered orally once daily.
Other Names:
  • Zytiga
  • Yonsa

Drug: Prednisone

(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.

(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required.


Drug: Methylprednisolone
For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
Other Name: Medrol

Experimental: Part 2: Relugolix plus Apalutamide
Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.
Drug: Relugolix

(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.

(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.

Other Names:
  • MVT-601
  • TAK-385
  • T-1331285
  • RVT-601
  • Orgovyx

Drug: Apalutamide
Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
Other Name: Erleada

Experimental: Part 3: Relugolix plus Docetaxel with or without Prednisone
Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.
Drug: Relugolix

(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.

(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.

Other Names:
  • MVT-601
  • TAK-385
  • T-1331285
  • RVT-601
  • Orgovyx

Drug: Prednisone

(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.

(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required.


Drug: Docetaxel
Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
Other Names:
  • Docefrez
  • Taxotere




Primary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: Baseline through Week 13 ]
    Parts 1, 2, and 3


Secondary Outcome Measures :
  1. Mean Testosterone Serum Concentrations at Baseline (Day 1), Week 5, and Week 13 [ Time Frame: Baseline (Day 1), Week 5, and Week 13 ]
    Parts 1 and 2

  2. Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Week 5, and Week 13 [ Time Frame: Baseline (Day 1), Week 5, and Week 13 ]
    Parts 1 and 2

  3. Relugolix Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 [ Time Frame: Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 ]
    Part 2

  4. Apalutamide and N-desmethyl Apalutamide Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 [ Time Frame: Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 ]
    Part 2

  5. Mean Testosterone Serum Concentrations at Baseline (Day 1), Mid-Treatment, and Week 13 [ Time Frame: Baseline (Day 1), Mid-Treatment, and Week 13 ]
    Part 3

  6. Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13 [ Time Frame: Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13 ]
    Part 3

  7. Relugolix Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel [ Time Frame: Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel ]
    Part 3

  8. Docetaxel Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel [ Time Frame: Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel ]
    Part 3

  9. Incidence of Adverse Events [ Time Frame: Up to 52 weeks ]
    Parts 1, 2, and 3



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. A diagnosis of adenocarcinoma of the prostate confirmed by histologic or cytologic evidence and with a documented medical history of either:

    • mCSPC (Parts 1, 2, and 3) defined as having at least two of three risk factors at the baseline (Day 1) visit:

      • Total Gleason score of ≥ 6; and
      • Presence of ≥ 2 metastatic lesions on bone scan; OR
      • Radiologic evidence of measurable visceral metastases with exception of hepatic metastases.
    • nmCRPC (Part 2 only) defined as disease progression despite maintaining castration levels of testosterone with androgen deprivation therapy (ADT), as evidenced by an increase in consecutive prostate-specific antigen (PSA) concentrations (2 measurements, at least one week apart).
    • mCRPC (Parts 1 and 3) defined as disease progression despite maintaining castration levels of testosterone with ADT:

      • An increase in consecutive PSA (2 measurements at least 1 weeks apart);
      • Worsening clinical symptoms;
      • Radiologic evidence demonstrating enlarged metastatic lesions or the development of new metastases.
  2. Currently receiving standard-of-care treatment of leuprolide acetate (3-, 4-, or 6-month injections [intramuscular Lupron or subcutaneous Eligard]) or a gonadotropin-releasing hormone (GnRH) receptor antagonist (such as degarelix) in combination with:

    • Part 1: abiraterone acetate 1000 mg or fine-particle abiraterone acetate 500 mg once daily plus prednisone 5 mg once daily for participants with mCSPC or twice daily for participants with mCRPC or methylprednisolone 4 mg once daily and in whom abiraterone has been well tolerated (that is, without evidence of hepatotoxicity requiring dose adjustment for abiraterone).
    • Part 2: apalutamide 240 mg once daily and in whom apalutamide has been well tolerated (that is, without a fracture, fall, or seizure episode or need to dose adjust due to any adverse events).
    • Part 3: docetaxel 75 mg/m2 and in whom docetaxel has been well tolerated (that is, no evidence of hypersensitivity reaction, febrile neutropenia or neutrophils < 500 cells/mm3 for more than 1 week, severe or cumulative cutaneous reactions, or moderate neurosensory signs and/or symptoms despite dose reduction).

Key Exclusion Criteria:

A patient will not be eligible for inclusion in the study if any of the following criteria apply:

  1. A medical history of brain or hepatic metastases based on radiologic evidence or a medical history of surgical castration;
  2. Received combination treatment with a GnRH analog or GnRH receptor antagonist with either abiraterone acetate plus a corticosteroid (Part 1) or apalutamide (Part 2) in patients with mCSPC (Part 1 and Part 2) or nmCRPC (Part 2) for a total duration > 24 months or in patients with mCRPC (Part 1) for a total duration > 6 months;
  3. Is scheduled or anticipates being scheduled for major surgery during the study treatment period;
  4. A current diagnosis of a malignancy other than prostate cancer, with the exception of any of the following:

    • Adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of any type;
    • Adequately treated Stage I cancer that is currently in remission and has been in remission for ≥ 2 years;
    • Any other cancer from which the patient has been disease-free for ≥ 3 years;
  5. Abnormal clinical laboratory test value(s) at the screening visit or prior to the baseline (Day 1) visit including:

    • Serum creatinine > 2.0 mg/dL;
    • Platelets < 100 × 103/μL;
    • Hemoglobin < 10.0 g/dL;
    • Leukocytes (WBC) < 3 × 103/μL;
    • Absolute neutrophil count < 1.5 × 103/μL;
    • Hemoglobin A1c (HbA1c) > 8%; Note (Part 3 only): Transfusions and/or administration of growth factors are permitted as indicated for the clinical management of docetaxel-related hematologic effects and in accordance with the investigator's judgement.
  6. Known hepatic disease, including alcoholic liver disease or viral hepatitis such as hepatitis A (hepatitis A virus IgM positive), chronic hepatitis B (HbsAg positive), or chronic hepatitis C (HCV antibody positive, confirmed by HCV RNA) or clinical signs of hepatic disease such as jaundice;
  7. A medical history within 6 months prior to the screening visit or a current diagnosis of any of the following:

    • Myocardial infarction;
    • Unstable angina;
    • Unstable symptomatic ischemic heart disease;
    • Congestive heart failure classified as NYHA class III or IV heart failure;
    • Thromboembolic event(s) (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular event[s]);
    • Any other significant cardiac condition (eg, pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease);
  8. An abnormal ECG
  9. Uncontrolled hypertension
  10. Hypotension
  11. Bradycardia
  12. Positive HIV
  13. Medical history of a bleeding disorder or current clinical evidence of gastrointestinal bleeding or active bleeding from another anatomical location.
  14. A medical history within 1 year of the screening visit of drug or alcohol abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders V
  15. Received an investigational drug within 28 days or 5 half-lives, whichever is longer, prior to the baseline (Day 1) visit;
  16. Prior use of any prohibited medication(s) and restrictive medication(s) without the appropriate washout period or use of a prohibited medication during the study treatment period is planned;
  17. A contraindication or known history of hypersensitivity to any of the study treatments or components thereof, or has a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates study participation;
  18. Any other medical or psychiatric condition that, in the opinion of the investigator, would interfere with accomplishing the study objectives or the patient completing the study;
  19. Is a study site employee or is a primary family member (spouse, parent, child, or sibling) of a site employee involved in the conduct of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04666129


Contacts
Layout table for location contacts
Contact: Clinical Trials at Myovant 650-278-8743 ClinicalTrials@Myovant.com

Locations
Layout table for location information
United States, Arizona
Urological Associates of Southern Arizona, P.C. Recruiting
Tucson, Arizona, United States, 85741
United States, Arkansas
Arkansas Urology Recruiting
Little Rock, Arkansas, United States, 72211
United States, Colorado
Colorodo Clinical Research Recruiting
Lakewood, Colorado, United States, 80228
United States, Maryland
Chesapeake Urology Research Associates Completed
Baltimore, Maryland, United States, 21204
United States, Massachusetts
University of Massachusetts Medical School Recruiting
Worcester, Massachusetts, United States, 01655
United States, New Jersey
New Jersey Urology Recruiting
Saddle Brook, New Jersey, United States, 07663
New Jersey Urology Not yet recruiting
Voorhees, New Jersey, United States, 08043
United States, New York
Clinical Research Alliance, Inc. Recruiting
Westbury, New York, United States, 11590
United States, North Carolina
Alliance Urology Recruiting
Greensboro, North Carolina, United States, 27403
Wake Forest Baptist Health Recruiting
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Clinical Research Solutions Recruiting
Middleburg Heights, Ohio, United States, 44130
United States, Pennsylvania
Center for Advanced Urology, LLP d/b/a: MidLantic Urology Recruiting
Bala-Cynwyd, Pennsylvania, United States, 19004
Keystone Urology Specialists Recruiting
Lancaster, Pennsylvania, United States, 17604
United States, South Carolina
Carolina Urologic Research Center Recruiting
Myrtle Beach, South Carolina, United States, 29572
United States, Tennessee
Urology Associates, P.C. Recruiting
Nashville, Tennessee, United States, 37209
United States, Texas
UT Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Urology San Antonio Recruiting
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Myovant Sciences GmbH
Investigators
Layout table for investigator information
Study Director: Myovant Medical Monitor Myovant Sciences
Layout table for additonal information
Responsible Party: Myovant Sciences GmbH
ClinicalTrials.gov Identifier: NCT04666129    
Other Study ID Numbers: MVT-601-049
First Posted: December 14, 2020    Key Record Dates
Last Update Posted: September 6, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Myovant Sciences GmbH:
mCRPC
mCSPC
Relugolix
Abiraterone
Prednisone
Leuprolide acetate
nmCRPC
Apalutamide
Docetaxel
Degarelix
Methylprednisolone
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Hypersensitivity
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Immune System Diseases
Prednisone
Methylprednisolone
Docetaxel
Relugolix
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Androgen Antagonists